ESSA Pharma, Inc.
(TSX Venture Exchange : EPIX)

( )
EPIX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
BMYBristol-Myers Squibb Co. -0.08%66.731.0%$727.56m
JNJJohnson & Johnson 0.58%149.060.7%$722.06m
PFEPfizer Inc. -0.25%40.510.9%$619.95m
MRKMerck & Co., Inc. -0.22%90.980.7%$583.46m
ABBVAbbVie, Inc. -1.40%88.012.3%$531.92m
LLYEli Lilly & Co. -1.29%139.611.1%$417.51m
APLSApellis Pharmaceuticals, Inc. 0.30%40.500.0%$108.33m
AZNAstraZeneca Plc 1.62%51.331.2%$100.08m
NVSNovartis AG 0.88%95.940.2%$99.68m
GSKGlaxoSmithKline Plc 1.55%47.890.2%$82.35m
SNYSanofi 0.10%51.240.2%$75.45m
NVONovo Nordisk A/S -0.02%61.300.1%$67.09m
RETAReata Pharmaceuticals, Inc. -2.24%211.433.5%$65.51m
KRTXKaruna Therapeutics, Inc. 9.17%104.520.0%$64.70m
TPTXTurning Point Therapeutics, Inc. 2.72%59.950.0%$42.12m

Company Profile

ESSA Pharma, Inc. engages in the development of small molecule drugs for prostate cancer. It focuses on producing drugs which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR), potentially overcoming the known AR-dependent resistance mechanisms of castration-resistant prostate cancer (CRPC), and providing CRPC patients with the potential for increased progression-free and overall survival. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.